Published in Proteomics on August 01, 2013
Applications of hydrogen/deuterium exchange MS from 2012 to 2014. Anal Chem (2014) 1.16
Inhibition of nutlin-resistant HDM2 mutants by stapled peptides. PLoS One (2013) 0.85
Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. J Phys Chem Lett (2016) 0.75
Discovery of a novel ligand that modulates the protein-protein interactions of the AAA+ superfamily oncoprotein reptin. Chem Sci (2015) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Drug discovery and p53. Drug Discov Today (2003) 2.34
Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Cell Cycle (2011) 2.25
Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell (2006) 2.09
Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol (2002) 1.67
DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem (2002) 1.59
Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle (2009) 1.52
Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle (2010) 1.51
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem (2002) 1.50
The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics (2004) 1.42
Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe (2013) 1.41
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet (2011) 1.39
The Mdm2 and p53 genes are conserved in the Arachnids. Cell Cycle (2010) 1.36
The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol (2003) 1.33
Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res (2003) 1.32
Hypoxia attenuates the p53 response to cellular damage. Oncogene (2003) 1.31
Defensins knowledgebase: a manually curated database and information source focused on the defensins family of antimicrobial peptides. Nucleic Acids Res (2006) 1.28
Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res (2010) 1.27
The crystal structure of the AAA domain of the ATP-dependent protease FtsH of Escherichia coli at 1.5 A resolution. Structure (2002) 1.22
CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem (2009) 1.19
Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett (2011) 1.19
DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and membrane blebbing. J Biol Chem (2008) 1.19
Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol Cell Biol (2004) 1.16
Comparative study of overlapping genes in bacteria, with special reference to Rickettsia prowazekii and Rickettsia conorii. Int J Syst Evol Microbiol (2005) 1.14
Structural and functional analysis of phosphothreonine-dependent FHA domain interactions. Structure (2010) 1.13
The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours? Semin Cancer Biol (2009) 1.13
The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) (2009) 1.12
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci (2004) 1.09
Conformational flexibility of Mycobacterium tuberculosis thioredoxin reductase: crystal structure and normal-mode analysis. Acta Crystallogr D Biol Crystallogr (2005) 1.09
Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem (2002) 1.07
Activation of macrophages by gliadin fragments: isolation and characterization of active peptide. J Leukoc Biol (2002) 1.05
Drug discovery and mutant p53. Trends Cell Biol (2010) 1.04
p63: the phantom of the tumor suppressor. Cell Cycle (2007) 1.04
New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun (2005) 1.02
Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep (2003) 1.01
The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members. Mol Cell Biol (2007) 1.01
A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem (2009) 1.01
Insight into the assembly properties and functional organisation of the magnetotactic bacterial actin-like homolog, MamK. PLoS One (2012) 1.00
How phosphorylation controls p53. Cell Cycle (2011) 0.99
Characterization of the lectin from females of Phlebotomus duboscqi sand flies. Eur J Biochem (2002) 0.98
Structure-dependent charge density as a determinant of antimicrobial activity of peptide analogues of defensin. Biochemistry (2009) 0.97
Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle (2008) 0.97
Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. Biochemistry (2002) 0.97
Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J (2009) 0.97
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection. J Biol Chem (2008) 0.96
The emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling landscape. Sci Signal (2013) 0.94
Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations. Structure (2010) 0.94
Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med (2005) 0.94
The p53 inducing drug dosage may determine quiescence or senescence. Aging (Albany NY) (2010) 0.94
Protein patterns of pig oocytes during in vitro maturation. Biol Reprod (2004) 0.93
Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer (2013) 0.91
Effective removal of nonionic detergents in protein mass spectrometry, hydrogen/deuterium exchange, and proteomics. Anal Chem (2010) 0.91
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos (2012) 0.91
Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting. Biochim Biophys Acta (2012) 0.90
Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol (2005) 0.90
Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem J (2004) 0.90
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J Immunol Methods (2012) 0.90
Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol (2009) 0.90
Conformational dynamics of the bovine mitochondrial ADP/ATP carrier isoform 1 revealed by hydrogen/deuterium exchange coupled to mass spectrometry. J Biol Chem (2010) 0.90
A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol (2010) 0.89
On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J Mol Biol (2005) 0.89
The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury. FEBS J (2006) 0.89
Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced cytotoxicity to mammalian cells. Chembiochem (2008) 0.89
Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J (2006) 0.89
p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle (2011) 0.89
Primary and 3-D modelled structures of two cyclotides from Viola odorata. Phytochemistry (2003) 0.88
DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation. Mol Cancer (2010) 0.88
The tick plasma lectin, Dorin M, is a fibrinogen-related molecule. Insect Biochem Mol Biol (2006) 0.88
Modified electrophoretic and digestion conditions allow a simplified mass spectrometric evaluation of disulfide bonds. J Mass Spectrom (2009) 0.88
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle (2011) 0.87
In vitro selection of mutant HDM2 resistant to Nutlin inhibition. PLoS One (2013) 0.87
The role of modelling in identifying drug targets for diseases of the cell cycle. J R Soc Interface (2006) 0.87
Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Lett (2013) 0.87
An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis. J Proteome Res (2012) 0.87
Stability of the core domain of p53: insights from computer simulations. BMC Bioinformatics (2008) 0.87
Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol (2004) 0.86
Aspartic protease nepenthesin-1 as a tool for digestion in hydrogen/deuterium exchange mass spectrometry. Anal Chem (2014) 0.86
Proteome study of Francisella tularensis live vaccine strain-containing phagosome in Bcg/Nramp1 congenic macrophages: resistant allele contributes to permissive environment and susceptibility to infection. Proteomics (2002) 0.86
New insights into p53 based therapy. Discov Med (2011) 0.86
Molecular rotors as conditionally fluorescent labels for rapid detection of biomolecular interactions. J Am Chem Soc (2014) 0.86
Identification of heme binding protein complexes in murine erythroleukemic cells: study by a novel two-dimensional native separation -- liquid chromatography and electrophoresis. Proteomics (2005) 0.85
Chemical genetics approach to identify peptide ligands that selectively stimulate DAPK-1 kinase activity. Biochemistry (2007) 0.85
Structural basis for the 14-3-3 protein-dependent inhibition of the regulator of G protein signaling 3 (RGS3) function. J Biol Chem (2011) 0.85
ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1. FEBS J (2008) 0.85
Recombinant immobilized rhizopuspepsin as a new tool for protein digestion in hydrogen/deuterium exchange mass spectrometry. Rapid Commun Mass Spectrom (2009) 0.85
Separation of nuclear protein complexes by blue native polyacrylamide gel electrophoresis. Electrophoresis (2006) 0.85
Inhibition of nutlin-resistant HDM2 mutants by stapled peptides. PLoS One (2013) 0.85
Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry. J Am Soc Mass Spectrom (2011) 0.85
CK2-site phosphorylation of p53 is induced in DeltaNp63 expressing basal stem cells in UVB irradiated human skin. Cell Cycle (2006) 0.84
The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J Mol Biol (2010) 0.84
Mdm2 in evolution. Genes Cancer (2012) 0.84
The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization. Mol Cell Biochem (2009) 0.84
Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem (2004) 0.84
A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1. J Biol Chem (2011) 0.84
The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain. J Biol Chem (2004) 0.84